D.E. Shaw & Co’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

D.E. Shaw & Co’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,528	Closed	-$425K	–	3838
2020 Q2	$425K	Buy	+2,528	New	+$273K	﹤0.01%	3469

Other funds holding BCLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co's BCLI Position: Q3 2020 in Review

D.E. Shaw & Co sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2020, closing a stake of 2,528 shares — an estimated $425K sold.

D.E. Shaw & Co first reported a position in BCLI in Q2 2020 and held it in 1 quarter. The position peaked at $425K in Q2 2020. 80 funds tracked by Wall St. Rank hold BCLI as of Q3 2020.

D.E. Shaw & Co reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2020 after selling out during the quarter.
D.E. Shaw & Co sold 2,528 BRAINSTORM CELL THERAPUTC shares in Q3 2020, an estimated $425K.
D.E. Shaw & Co first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 1 quarter.
D.E. Shaw & Co's BRAINSTORM CELL THERAPUTC position peaked at $425K in Q2 2020.
80 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2020.

Based on D.E. Shaw & Co's 13F filing for Q3 2020, filed 16 Nov 2020.